Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
    • MIS Systems
    • Online Data Verification
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
Home > News & Updates > Regulatory Updates > Drugs > Policy for Inspection of Manufacturing Site Abroad

Policy for Inspection of Manufacturing Site Abroad

Asad Ullah Drugs, News & Updates, Notifications, Regulatory Updates July 6, 2022July 6, 2022

Policy Board of the Drug Regulatory Authority of Pakistan (DRAP) has given policy guidelines for inspections of manufacturers keeping in view the suggestions/guidelines of WHO for reliance on other regulatory authorities. Accordingly, the revised “Policy for inspections of manufacturers abroad” as approved by the Policy Board under Section 11 (I) (a) of the DRAP Act, 2012, as under:-

Current-Policy-fo-inspectionDownload

Share this:

  • Twitter
  • Facebook
  • ← DRAP notified National Pharmacovigilance Centre (NPC) under the Pharmacovigilance Rules, 2022
  • Draft amendments in rules framed under Drug Act 1976 (for comments within 7 days of publication of SRO). →
  • DRAP at a Glance
    • What We Do?
    • Vision & Mission
    • CEO’s Message
  • Organization
    • Organizational Structure
    • Divisions
    • Policy Board
    • Members of Authority
    • Information and Transparency
    • Strategic Plan
  • Legislation
    • Acts
    • Rules
    • Regulations
    • SROs
    • Notifications
  • Boards and Committees
    • Central Licensing Board
    • Registration Board
    • Medical Devices Board
    • Enlistment Evaluation Committee
    • Clinical Studies Committee
    • Pharmacovigilance RAE Committee
    • Committee on Advertisements
  • Quality Management System
    • Quality Policy
    • Management Reviews
  • Drugs
  • Medical Devices
  • Alternative Medicines
  • Controlled Substances
  • Licensing and Inspections
  • Clinical Trials
  • Pharmacovigilance
  • Advertisements
  • General

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:30AM to 04:30PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem